US Patent 11065195 Topical composition
Patent 11065195 was granted and assigned to MC2 Therapeutics Limited on July, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+271 characters)
Article
Patent abstract
A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.
Edits on 7 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110651950
Date of Patent
July 20, 2021
0Patent Application Number
162877790
Date Filed
February 27, 2019
0Official Website
Patent Primary Examiner
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
110651950
Date of Patent
July 20, 2021
0Patent Application Number
162877790
Date Filed
February 27, 2019
0Official Website
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 13 Feb, 2022
Golden AI
Edits made to:
Infobox (+10 properties)
US Patent 11065195 Topical composition
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11065195
Date of patent
July 20, 2021
Patent application number
16287779
Date Filed
February 27, 2019
Patent primary examiner
Find more entities like US Patent 11065195 Topical composition
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
